Six years after signing a U.S. marketing partnership with Hikma Pharma for its seasonal allergy spray Ryaltris, India’s Glenmark is now going it alone.
Back in 2020, Glenmark penned a deal with Hikma as its U.S. distribution partner for Ryaltris while the drug was still in development.
The FDA signed off on the spray in 2022 and since then, Hikma has been selling the product in the U.S.
But in a marketing shift announced April 1, Glenmark’s U.S. division has dropped its partner model for the med and will “manage end-to-end commercialization and distribution for Ryaltris in the United States.”
“This marks a meaningful step in Glenmark's continued expansion in the region with a sustainable approach to building a strong, direct commercial U.S. based presence,” the company said in a release.
From April 1, Glenmark will directly lead brand strategy, market access, and customer engagement for the drug in the U.S. The spray generated nearly $100 million across all markets last year.
"The commercialization by Glenmark for Ryaltris in the United States is an important step forward for the growth of our company,” Glenmark’s Marc Kikuchi, President & Business Head, North America, said in a statement.
“It allows us greater operational direction in how we engage the market and support healthcare providers and patients across the nation,” Kikuchi added. “Today's announcement also marks a significant moment in our broader effort to strengthen our innovative businesses in the U.S. and build a more direct, sustainable commercial presence over time.”